Strata Critical Medical Inc Warrants
SRTAW
SRTAW was delisted on the 6th of May, 2026.
8 hedge funds and large institutions have $548K invested in Strata Critical Medical Inc Warrants in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
4% less ownership
Funds ownership: 7.7% → 3.7% (-4%)
27% less funds holding
Funds holding: 11 → 8 (-3)
47% less capital invested
Capital invested by funds: $1.03M → $548K (-$479K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$284K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$188K |
| 3 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$62.5K |
| 4 |
Morgan Stanley
New York
|
-$18.1K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1.64K |
SRTAW Hedge Fund Activity: Q3 2024 in Review
8 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in Strata Critical Medical Inc Warrants (SRTAW) for Q3 2024, worth a combined $548K — down 47% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SRTAW and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $284K sold.
- 8 institutional investors held Strata Critical Medical Inc Warrants (SRTAW) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $548K of Strata Critical Medical Inc Warrants stock for Q3 2024, down 47% quarter-over-quarter.
- 0 funds opened new Strata Critical Medical Inc Warrants positions in Q3 2024 and 3 closed out, a net change of -3 holders.
- The largest Strata Critical Medical Inc Warrants seller in Q3 2024 was Goldman Sachs, an estimated $284K sold.
Based on aggregated 13F filings for Q3 2024.